VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
2.870
-0.010 (-0.35%)
Dec 3, 2024, 10:05 AM EST - Market open

VYNE Therapeutics Revenue

VYNE Therapeutics had revenue of $121.00K in the quarter ending September 30, 2024, with 6.14% growth. This brings the company's revenue in the last twelve months to $493.00K, up 39.27% year-over-year. In the year 2023, VYNE Therapeutics had annual revenue of $424.00K, down -11.11%.

Revenue (ttm)
$493.00K
Revenue Growth
+39.27%
P/S Ratio
232.30
Revenue / Employee
$49,300
Employees
10
Market Cap
42.19M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023424.00K-53.00K-11.11%
Dec 31, 2022477.00K-454.00K-48.76%
Dec 31, 2021931.00K-20.06M-95.57%
Dec 31, 202020.99M20.55M4,638.83%
Dec 31, 2019443.00K-3.15M-87.68%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
NeueHealth 996.89M
FibroGen 180.02M
Celularity 42.69M
Accelerate Diagnostics 11.91M
LAVA Therapeutics 7.40M
Actinium Pharmaceuticals 81.00K
Revenue Rankings